Key Points
- BeOne Medicines SVP Chan Lee sold 1,115 shares at $375 each, worth $418,125, under a pre-arranged Rule 10b5-1 plan. The sale follows three earlier disposals totaling roughly $1.5 million.
- BeOne’s latest quarterly results beat expectations, with EPS of $2.05 versus $1.40 forecast and revenue of $1.71 billion versus $1.66 billion expected. Analysts project $8.81 in full-year EPS, though the stock trades at an elevated price-to-earnings ratio above 60.
- Despite insider selling, analyst sentiment remains positive: the stock has an average “Buy” rating and a consensus price target of $404.14, while JPMorgan recently raised its target to $445.
BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) SVP Chan Lee sold 1,115 shares of BeOne Medicines stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $375.00, for a total value of $418,125.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Chan Henry Lee also recently made the following trade(s):
- On Tuesday, August 11th, Chan Lee sold 2,666 shares of BeOne Medicines stock. The shares were sold at an average price of $360.00, for a total value of $959,760.00.
- On Thursday, July 30th, Chan Lee sold 1,044 shares of BeOne Medicines stock. The stock was sold at an average price of $323.69, for a total value of $337,932.36.
- On Wednesday, July 8th, Chan Lee sold 664 shares of BeOne Medicines stock. The shares were sold at an average price of $302.46, for a total value of $200,833.44.
BeOne Medicines Stock Performance
Shares of BeOne Medicines stock opened at $358.07 on Friday. The stock has a market capitalization of $39.31 billion, a price-to-earnings ratio of 63.04 and a beta of 0.61. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.40 and a quick ratio of 3.06. The business has a 50-day moving average of $353.95 and a 200 day moving average of $316.23. BeOne Medicines Ltd. - Sponsored ADR has a 12 month low of $253.95 and a 12 month high of $385.22.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $2.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.40 by $0.65. The company had revenue of $1.71 billion for the quarter, compared to analyst estimates of $1.66 billion. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. As a group, sell-side analysts forecast that BeOne Medicines Ltd. - Sponsored ADR will post 8.81 earnings per share for the current year.
Institutional Trading of BeOne Medicines
A number of large investors have recently made changes to their positions in ONC. Capital International Investors lifted its stake in BeOne Medicines by 1.3% in the fourth quarter. Capital International Investors now owns 5,113,866 shares of the company's stock worth $1,553,909,000 after acquiring an additional 67,808 shares during the last quarter. Bank of America Corp DE lifted its position in shares of BeOne Medicines by 7.0% during the 1st quarter. Bank of America Corp DE now owns 405,273 shares of the company's stock worth $120,354,000 after purchasing an additional 26,441 shares during the last quarter. Baird Financial Group Inc. grew its stake in shares of BeOne Medicines by 5.5% during the second quarter. Baird Financial Group Inc. now owns 368,978 shares of the company's stock worth $105,148,000 after purchasing an additional 19,327 shares in the last quarter. Candriam S.C.A. increased its holdings in BeOne Medicines by 31.7% in the first quarter. Candriam S.C.A. now owns 259,731 shares of the company's stock valued at $77,132,000 after buying an additional 62,470 shares during the last quarter. Finally, First Trust Advisors LP raised its stake in BeOne Medicines by 91.9% in the first quarter. First Trust Advisors LP now owns 241,426 shares of the company's stock valued at $71,696,000 after buying an additional 115,601 shares in the last quarter. 48.55% of the stock is currently owned by hedge funds and other institutional investors.
Key BeOne Medicines News
Here are the key news stories impacting BeOne Medicines this week:
- Positive Sentiment: JPMorgan raised its price target on BeOne Medicines to $445 from $425 and maintained an “overweight” rating, implying substantial upside from recent levels. This reinforces the broader Wall Street consensus, which remains “Buy.” JPMorgan raises BeOne Medicines price target
- Positive Sentiment: Investor’s Business Daily said BeOne shares are approaching potential buy points, highlighting continued momentum in BRUKINSA, the company’s blockbuster cancer drug, which generated $1.2 billion in second-quarter sales. BeOne Medicines poised to hit early buy points
- Neutral Sentiment: BeOne’s latest quarterly results exceeded expectations, with earnings of $2.05 per share versus a $1.40 consensus estimate and revenue of $1.71 billion versus $1.66 billion. Analysts expect approximately $8.81 in full-year earnings per share, although the stock’s valuation remains elevated at more than 60 times earnings.
- Negative Sentiment: Insider Xiaodong Wang sold 31,028 shares for approximately $11.3 million, reducing his direct ownership by 50%. Separately, Senior Vice President Chan Lee sold 1,115 shares for about $418,000. Both transactions were executed under pre-arranged Rule 10b5-1 plans, which lessens—but does not eliminate—their significance as a sentiment signal. BeOne Medicines insider sales
Analyst Ratings Changes
A number of equities research analysts have issued reports on the stock. Weiss Ratings upgraded shares of BeOne Medicines from a "sell (d-)" rating to a "hold (c+)" rating in a report on Tuesday, September 22nd. Nomura upgraded shares of BeOne Medicines to a "strong-buy" rating in a research note on Monday, July 27th. TD Cowen upped their price objective on BeOne Medicines from $424.00 to $454.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Wolfe Research reiterated an "outperform" rating and issued a $370.00 price objective on shares of BeOne Medicines in a research note on Monday, August 10th. Finally, Truist Financial increased their price objective on BeOne Medicines from $416.00 to $418.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $404.14.
Read Our Latest Analysis on ONC
BeOne Medicines Company Profile
(
Get Free Report)
BeOne Medicines Ltd. (NASDAQ: ONC) is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for people with cancer. The company operates across the research and development, clinical testing, regulatory and commercial stages of the biopharmaceutical industry, with an emphasis on treatments for blood cancers and solid tumors.
Its marketed portfolio includes BRUKINSA (zanubrutinib), a Bruton's tyrosine kinase inhibitor used to treat several B-cell malignancies, and TEVIMBRA (tislelizumab), an immunotherapy targeting the PD-1 pathway for certain cancers.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
